Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 3, 2024, by Trevi Therapeutics, Inc., a Delaware corporation. The filing reports on the announcement of positive results from a Human Abuse Potential (HAP) study for the company's oral nalbuphine product candidate (Haduvio).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory milestones.
Material Changes and Clinical Results
The primary event reported is the completion of a randomized, double-blind, double-dummy, active and placebo-controlled five-way crossover HAP study in recreational drug users. The study compared oral nalbuphine against IV butorphanol and placebo.
- Primary Endpoint (Drug Liking): Clinical doses of oral nalbuphine (81mg and 162mg) demonstrated statistically significant lower "Drug Liking" scores compared to the active comparator (6mg IV butorphanol).
- Supratherapeutic Dose: The 486mg dose showed numerically lower "Drug Liking" than IV butorphanol but did not reach statistical significance.
- Safety: No serious adverse events were reported in the study.
- Secondary Endpoints: Results for "Take Drug Again," "I Feel High," and "I Feel Good" were generally consistent with the primary endpoint, showing lower scores for oral nalbuphine compared to IV butorphanol.
| Group | Mean Emax "Drug Liking" | P-value vs. IV Butorphanol |
|---|---|---|
| Placebo | 51.8 | p<0.0001 |
| IV Butorphanol 6mg | 82.3 | — |
| Oral Nalbuphine 81mg | 71.2 | p<0.0001 |
| Oral Nalbuphine 162mg | 74.5 | p=0.0008 |
| Oral Nalbuphine 486mg | 81.1 | p=0.3221 |
Guidance, Outlook, and Risks
The results will be included in the 8-factor analysis of abuse potential for nalbuphine ER to inform scheduling considerations in any future New Drug Application (NDA) submission. The filing includes standard forward-looking statements regarding the success, cost, and timing of product development, regulatory views, and the company's ability to fund future operations. Risks include the uncertainty of clinical trial outcomes and cash runway estimates.
Investor Verification Checklist
- Verify the statistical significance of the 486mg supratherapeutic dose results in the full study report.
- Confirm the timeline for the submission of the 8-factor analysis to the FDA.
- Review the most recent Form 10-Q (ended September 30, 2024) for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Assess the regulatory implications of the "Drug Liking" scores on the potential scheduling classification of Haduvio.